Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (July 2016)
25 slides from Rennova Health's investor presentation, Jul 11, 2016
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Filed Pursuant to Rule 433 Registration No. 333-211515 July 11, 2016 Nasdaq: RNVA Diagnostics and Supportive Software Solutions to Healthcare Providers
Slide 2: Forward Looking Statements and Non-GAAP Information
Forward Looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the proposed public offering. Because this presentation is a summary, it does not contain all of the information you should consider before investing in our securities. We have filed a registration statemen
Slide 4: Offering Summary
Offering Summary Issuer: Rennova Health, Inc. Exchange & Ticker: NASDAQ: RNVA Approximately $10,000,000 of Units consisting of Convertible Preferred Expected Offering Size: Stock and Warrants or Common Stock and Warrants (including the 15% over-allotment option) Working capital and general corporate
Slide 5: Healthcare is Being Transformed
Healthcare is Being Transformed We are Rennova Health 5
Slide 6: Key Investment Highlights
Key Investment Highlights • Five-year history of operations with multiple significant milestones • Substantial and profitable revenues from our core lab testing business • We operate in a very sizable and well established market place • Focused strategic growth plan from a solid foundation • We have
Slide 7: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have
Slide 8: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers Our core business is diagnostics: Historically >90% of our revenue has been derived from diagnostics That is changing: Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Management Propri
Slide 9: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • 54% increase in monthly insured samples processed by our labs for the first two months of the second quarter of 2016 versus the average monthly insured samples for the first quarter of 2016. This increase in samples has resulted in: • 12%
Slide 10: Recent Developments
Recent Developments Supportive Software Solutions Segment • Our integrated software solution will result in a much more sustainable relationship with our customers • Added 29 new EHR clients in 2016 • 18 being added in the second quarter of 2016 • Launched Electronic Medication Administration Record
Slide 11: 2015 Accomplishments
2015 Accomplishments Completed Lab Development Supportive Software Development Merger & Nasdaq listing Launched in 4th Quarter of 2015: • Medical Mime EHR product & billing services designed for substance abuse treatment sector • CollabRx for cancer diagnostics and decision support • Rebranded to Re
Slide 12: Our Target Markets
Our Target Markets Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 million Americans are addicted to alcohol and ot
Slide 13: Rennova Health Licensing Map
Rennova Health Licensing Map 13
Slide 14: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 31 States o As of June 30, 2016, we possess Medicaid Licenses in 20 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Coventry (National Con
Slide 15: History in Numbers
History in Numbers $70,000,000 $59,429,000 $60,000,000 $50,000,000 $41,889,000 $40,000,000 $37,887,000 $30,000,000 $21,076,000 $19,749,000 $20,000,000 $14,775,000 $10,000,000 $3,993,000 $4,183,000 $3,714,000 $621,000 $- 2011 2012 2013 2014 2015 Adjusted Revenues Adjusted EBITDA Reconciliation of Adj
Slide 16: Select Income Statement Items
Select Income Statement Items Reconciliation of GAAP to Adjusted Measures (in thousands) 2011 2012 2013 2014 2015 GAAP Net Revenue $ 3,993 $ 21,076 $ 41,889 $ 57,928 $ 18,393 Reserve for Aged Accounts Receivable - - - 1,501 19,494 Adjusted Revenues $ 3,993 $ 21,076 $ 41,889 $ 59,429 $ 37,887 GAAP Pr
Slide 17: Strategy
Strategy 17
Slide 18: The Long Term Strategy
The Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by g
Slide 19: 2016 Goals
2016 Goals • Strengthen Core Diagnostic Business o Capitalize on recent disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (Direct to Consumer) testing – initial ambition, testosterone • Accelerate Growth and/or Launch: o Supportive
Slide 20: Online Training Program Launch to Deliver Increased Sales
Online Training Program Launch to Deliver Increased Sales Program Objectives: • Ensure consistency in messaging and information • Provide effective and easy to use platform • Make information accessible anytime and from anywhere • Enable opportunity for monitoring and assessment Initially for sales
Slide 21: Business Development Opportunities
Business Development Opportunities Epinex Diagnostics, Inc. Genomas Diabetes and rapid Genomics based diagnostic tests for providers diagnostics - drug & consumers management solution 21
Slide 22: Rennova Management
Rennova Management Seamus Lagan • 20 years experience in the restructuring, development and management of startup and small companies CEO Jason Adams • CFO in behavorial health sector and Senior Financial Management of public companies CFO Victoria Nemerson, Esq. • 25 years experience as a trial and
Slide 23: Board of Directors
Board of Directors Thomas Mika • 10 years as Chairman and CEO of a Nasdaq listed Company • Oversaw a number of public offerings. Chairman of Rennova, CEO of CollabRx (subsidiary) • Bachelor of Science degree in Microbiology, MBA Harvard Seamus Lagan • 20 years experience in the restructuring, develo
Slide 24: Capitalization at July 8, 2016
Capitalization at July 8, 2016 As of July 8, 2016 - Pro-Forma @ $0.54/Share: Common Shares Outstanding 14,782,557 Dilutive Potential Shares: Stock Options @ WAVG $6.03 17,465,675 Warrants 6,834,569 Convertible Debt 1,851,852 Convertible Preferred Stock 22,180,995 Dilutive Potential Shares Arising Fr
Slide 25: Key Investment Highlights
Key Investment Highlights • Five-year history of operations with multiple significant milestones • Substantial and profitable revenues from our core lab testing business • We operate in a very sizable and well established market place • Focused strategic growth plan based off a solid foundation • We